ID   TGFR2_HUMAN             Reviewed;         567 AA.
AC   P37173; B4DTV5; Q15580; Q6DKT6; Q99474;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 205.
DE   RecName: Full=TGF-beta receptor type-2;
DE            Short=TGFR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=TGF-beta type II receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type II;
DE            Short=TGF-beta receptor type II;
DE            Short=TbetaR-II;
DE   Flags: Precursor;
GN   Name=TGFBR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-439, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=1310899; DOI=10.1016/0092-8674(92)90152-3;
RA   Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.;
RT   "Expression cloning of the TGF-beta type II receptor, a functional
RT   transmembrane serine/threonine kinase.";
RL   Cell 68:775-785(1992).
RN   [2]
RP   ERRATUM.
RX   PubMed=1525823;
RA   Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.;
RL   Cell 70:1069-1069(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Glial cell;
RX   PubMed=7959019; DOI=10.1016/0378-1119(94)90178-3;
RA   Nikawa J.;
RT   "A cDNA encoding the human transforming growth factor beta receptor
RT   suppresses the growth defect of a yeast mutant.";
RL   Gene 149:367-372(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439.
RX   PubMed=8812462; DOI=10.1006/geno.1996.0471;
RA   Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W.P.,
RA   Harris C.C.;
RT   "The genomic structure of the gene encoding the human transforming
RT   growth factor beta type II receptor (TGF-beta RII).";
RL   Genomics 36:341-344(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439.
RX   PubMed=8840968;
RA   Lu S.-L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y.;
RT   "Genomic structure of the transforming growth factor beta type II
RT   receptor gene and its mutations in hereditary nonpolyposis colorectal
RT   cancers.";
RL   Cancer Res. 56:4595-4598(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439.
RC   TISSUE=Liver;
RX   PubMed=8973329; DOI=10.1016/S0378-1119(96)00501-X;
RA   Ogasa H., Noma T., Murata H., Kawai S., Nakazawa A.;
RT   "Cloning of a cDNA encoding the human transforming growth factor-beta
RT   type II receptor: heterogeneity of the mRNA.";
RL   Gene 181:185-190(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-36.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PROTEIN SEQUENCE OF 23-37.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF TGFBR1.
RX   PubMed=7774578;
RA   Wieser R., Wrana J.L., Massague J.;
RT   "GS domain mutations that constitutively activate T beta R-I, the
RT   downstream signaling component in the TGF-beta receptor complex.";
RL   EMBO J. 14:2199-2208(1995).
RN   [12]
RP   INTERACTION WITH ZFYVE9.
RX   PubMed=9865696; DOI=10.1016/S0092-8674(00)81701-8;
RA   Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.;
RT   "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta
RT   receptor.";
RL   Cell 95:779-791(1998).
RN   [13]
RP   HOMODIMERIZATION.
RX   PubMed=9472030; DOI=10.1083/jcb.140.4.767;
RA   Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.;
RT   "Oligomeric structure of type I and type II transforming growth factor
RT   beta receptors: homodimers form in the ER and persist at the plasma
RT   membrane.";
RL   J. Cell Biol. 140:767-777(1998).
RN   [14]
RP   INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-277.
RX   PubMed=11483955; DOI=10.1038/35087019;
RA   Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.;
RT   "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx
RT   that facilitates JNK activation.";
RL   Nat. Cell Biol. 3:708-714(2001).
RN   [15]
RP   INTERACTION WITH VPS39.
RX   PubMed=12941698; DOI=10.1093/emboj/cdg428;
RA   Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M.,
RA   Karpova T.S., McNally J.G., Roberts A.B.;
RT   "TLP, a novel modulator of TGF-beta signaling, has opposite effects on
RT   Smad2- and Smad3-dependent signaling.";
RL   EMBO J. 22:4465-4477(2003).
RN   [16]
RP   INTERACTION WITH TCTEX1D4.
RX   PubMed=16982625; DOI=10.1074/jbc.M608614200;
RA   Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T.,
RA   McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.;
RT   "Identification of Tctex2beta, a novel dynein light chain family
RT   member that interacts with different transforming growth factor-beta
RT   receptors.";
RL   J. Biol. Chem. 281:37069-37080(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   INTERACTION WITH SCUBE3.
RX   PubMed=21441952; DOI=10.1038/onc.2011.85;
RA   Wu Y.Y., Peck K., Chang Y.L., Pan S.H., Cheng Y.F., Lin J.C.,
RA   Yang R.B., Hong T.M., Yang P.C.;
RT   "SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the
RT   epithelial-mesenchymal transition in lung cancer.";
RL   Oncogene 30:3682-3693(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25893292; DOI=10.1038/onc.2015.100;
RA   Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H.,
RA   Lee J.H.;
RT   "Syntenin regulates TGF-beta1-induced Smad activation and the
RT   epithelial-to-mesenchymal transition by inhibiting caveolin-mediated
RT   TGF-beta type I receptor internalization.";
RL   Oncogene 35:389-401(2016).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 38-159 IN COMPLEX WITH
RP   TGF-BETA3, AND DISULFIDE BONDS.
RX   PubMed=11850637; DOI=10.1038/nsb766;
RA   Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P.;
RT   "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3
RT   complex.";
RL   Nat. Struct. Biol. 9:203-208(2002).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 49-159, AND DISULFIDE BONDS.
RX   PubMed=12121646; DOI=10.1016/S0969-2126(02)00780-3;
RA   Boesen C.C., Radaev S., Motyka S.A., Patamawenu A., Sun P.D.;
RT   "The 1.1 A crystal structure of human TGF-beta type II receptor ligand
RT   binding domain.";
RL   Structure 10:913-919(2002).
RN   [25]
RP   STRUCTURE BY NMR OF 38-159, AND DISULFIDE BONDS.
RX   PubMed=12939140; DOI=10.1021/bi034366a;
RA   Deep S., Walker K.P. III, Shu Z., Hinck A.P.;
RT   "Solution structure and backbone dynamics of the TGFbeta type II
RT   receptor extracellular domain.";
RL   Biochemistry 42:10126-10139(2003).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 43-149 IN COMPLEX WITH
RP   TGFBR1 AND TGFB3, AND DISULFIDE BONDS.
RX   PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039;
RA   Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C.,
RA   Schuermann J.P., Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.;
RT   "Cooperative assembly of TGF-beta superfamily signaling complexes is
RT   mediated by two disparate mechanisms and distinct modes of receptor
RT   binding.";
RL   Mol. Cell 29:157-168(2008).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 38-153 IN COMPLEX WITH
RP   TGFBR1 AND TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS.
RX   PubMed=20207738; DOI=10.1074/jbc.M109.079921;
RA   Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.;
RT   "Ternary complex of transforming growth factor-beta1 reveals isoform-
RT   specific ligand recognition and receptor recruitment in the
RT   superfamily.";
RL   J. Biol. Chem. 285:14806-14814(2010).
RN   [28]
RP   VARIANT HNPCC6 MET-315.
RX   PubMed=9590282; DOI=10.1038/ng0598-17;
RA   Lu S.-L., Kawabata M., Imamura T., Akiyama Y., Nomizu T., Miyazono K.,
RA   Yuasa Y.;
RT   "HNPCC associated with germline mutation in the TGF-beta type II
RT   receptor gene.";
RL   Nat. Genet. 19:17-18(1998).
RN   [29]
RP   VARIANT ESOPHAGEAL CANCER GLN-526.
RX   PubMed=10789724; DOI=10.1054/bjoc.1999.1178;
RA   Tanaka S., Mori M., Mafune K., Ohno S., Sugimachi K.;
RT   "A dominant negative mutation of transforming growth factor-beta
RT   receptor type II gene in microsatellite stable oesophageal
RT   carcinoma.";
RL   Br. J. Cancer 82:1557-1560(2000).
RN   [30]
RP   VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452, AND
RP   CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND
RP   MET-452.
RX   PubMed=11212236;
RA   Luecke C.D., Philpott A., Metcalfe J.C., Thompson A.M.,
RA   Hughes-Davies L., Kemp P.R., Hesketh R.;
RT   "Inhibiting mutations in the transforming growth factor beta type 2
RT   receptor in recurrent human breast cancer.";
RL   Cancer Res. 61:482-485(2001).
RN   [31]
RP   VARIANT ILE-191.
RX   PubMed=12202987; DOI=10.1007/s100380200069;
RA   Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T.,
RA   Matsumoto N., Ishikawa M., Niikawa N., Yoshiura K.;
RT   "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other
RT   types of variations in genes for transforming growth factor-beta1
RT   (TGF-beta1) and its signaling pathway.";
RL   J. Hum. Genet. 47:478-483(2002).
RN   [32]
RP   VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537, AND CHARACTERIZATION OF
RP   VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537.
RX   PubMed=15235604; DOI=10.1038/ng1392;
RA   Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N.,
RA   Morisaki T., Allard D., Varret M., Claustres M., Morisaki H.,
RA   Ihara M., Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G.,
RA   Ohta T., Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C.,
RA   Matsumoto N.;
RT   "Heterozygous TGFBR2 mutations in Marfan syndrome.";
RL   Nat. Genet. 36:855-860(2004).
RN   [33]
RP   VARIANTS LDS2 CYS-460 AND HIS-460.
RX   PubMed=16027248; DOI=10.1161/CIRCULATIONAHA.105.537340;
RA   Pannu H., Fadulu V.T., Chang J., Lafont A., Hasham S.N., Sparks E.,
RA   Giampietro P.F., Zaleski C., Estrera A.L., Safi H.J., Shete S.,
RA   Willing M.C., Raman C.S., Milewicz D.M.;
RT   "Mutations in transforming growth factor-beta receptor type II cause
RT   familial thoracic aortic aneurysms and dissections.";
RL   Circulation 112:513-520(2005).
RN   [34]
RP   VARIANTS LDS2 ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528.
RX   PubMed=15731757; DOI=10.1038/ng1511;
RA   Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T.,
RA   Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A.,
RA   Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y.,
RA   Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B.,
RA   De Paepe A.M., Dietz H.C.;
RT   "A syndrome of altered cardiovascular, craniofacial, neurocognitive
RT   and skeletal development caused by mutations in TGFBR1 or TGFBR2.";
RL   Nat. Genet. 37:275-281(2005).
RN   [35]
RP   VARIANT LDS2 ASN-446.
RX   PubMed=16251899; DOI=10.1038/sj.ejhg.5201502;
RA   Disabella E., Grasso M., Marziliano N., Ansaldi S., Lucchelli C.,
RA   Porcu E., Tagliani M., Pilotto A., Diegoli M., Lanzarini L.,
RA   Malattia C., Pelliccia A., Ficcadenti A., Gabrielli O., Arbustini E.;
RT   "Two novel and one known mutation of the TGFBR2 gene in Marfan
RT   syndrome not associated with FBN1 gene defects.";
RL   Eur. J. Hum. Genet. 14:34-38(2006).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328;
RP   ILE-373; MET-387 AND SER-490.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [38]
RP   VARIANTS LDS2 HIS-190; VAL-247; PRO-325; ARG-357 AND ILE-530.
RX   PubMed=19533785; DOI=10.1002/ajmg.a.32918;
RA   Chung B.H., Lam S.T., Tong T.M., Li S.Y., Lun K.S., Chan D.H.,
RA   Fok S.F., Or J.S., Smith D.K., Yang W., Lau Y.L.;
RT   "Identification of novel FBN1 and TGFBR2 mutations in 65 probands with
RT   Marfan syndrome or Marfan-like phenotypes.";
RL   Am. J. Med. Genet. A 149A:1452-1459(2009).
RN   [39]
RP   VARIANT LDS2 SER-510.
RX   PubMed=19883511; DOI=10.1186/1750-1172-4-24;
RA   Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R.,
RA   Calzavara-Pinton P.G., Barlati S., Colombi M.;
RT   "Loeys-Dietz syndrome type I and type II: clinical findings and novel
RT   mutations in two Italian patients.";
RL   Orphanet J. Rare Dis. 4:24-24(2009).
RN   [40]
RP   VARIANT LDS2 LYS-457.
RX   PubMed=20101701; DOI=10.1002/ajmg.a.33263;
RA   Muramatsu Y., Kosho T., Magota M., Yokotsuka T., Ito M., Yasuda A.,
RA   Kito O., Suzuki C., Nagata Y., Kawai S., Ikoma M., Hatano T.,
RA   Nakayama M., Kawamura R., Wakui K., Morisaki H., Morisaki T.,
RA   Fukushima Y.;
RT   "Progressive aortic root and pulmonary artery aneurysms in a neonate
RT   with Loeys-Dietz syndrome type 1B.";
RL   Am. J. Med. Genet. A 152:417-421(2010).
RN   [41]
RP   VARIANTS LDS2 PRO-308 AND ARG-521.
RX   PubMed=20358619; DOI=10.1002/ajmg.a.33356;
RA   Kirmani S., Tebben P.J., Lteif A.N., Gordon D., Clarke B.L.,
RA   Hefferan T.E., Yaszemski M.J., McGrann P.S., Lindor N.M.,
RA   Ellison J.W.;
RT   "Germline TGF-beta receptor mutations and skeletal fragility: a report
RT   on two patients with Loeys-Dietz syndrome.";
RL   Am. J. Med. Genet. A 152:1016-1019(2010).
RN   [42]
RP   VARIANTS LDS2 GLN-306 DELINS HIS-GLU; ARG-377; PHE-449 AND ARG-514.
RX   PubMed=22113417; DOI=10.1038/jhg.2011.130;
RA   Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K.,
RA   Lee H.J., Kim D.K.;
RT   "Clinical features and genetic analysis of Korean patients with Loeys-
RT   Dietz syndrome.";
RL   J. Hum. Genet. 57:52-56(2012).
RN   [43]
RP   VARIANTS LDS2 VAL-509 AND PHE-510.
RX   PubMed=21949523; DOI=10.3345/kjp.2011.54.6.272;
RA   Ha J.S., Kim Y.H.;
RT   "A sporadic case of Loeys-Dietz syndrome type I with two novel
RT   mutations of the TGFBR2 gene.";
RL   Korean J. Pediatr. 54:272-275(2011).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase forming with the
CC       TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-
CC       promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and
CC       TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell
CC       surface to the cytoplasm and is thus regulating a plethora of
CC       physiological and pathological processes including cell cycle
CC       arrest in epithelial and hematopoietic cells, control of
CC       mesenchymal cell proliferation and differentiation, wound healing,
CC       extracellular matrix production, immunosuppression and
CC       carcinogenesis. The formation of the receptor complex composed of
CC       2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the
CC       cytokine dimer results in the phosphorylation and the activation
CC       of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1
CC       phosphorylates SMAD2 which dissociates from the receptor and
CC       interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently
CC       translocated to the nucleus where it modulates the transcription
CC       of the TGF-beta-regulated genes. This constitutes the canonical
CC       SMAD-dependent TGF-beta signaling cascade. Also involved in non-
CC       canonical, SMAD-independent TGF-beta signaling pathways.
CC       {ECO:0000269|PubMed:7774578}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3
CC       homodimeric ligands assemble a functional receptor composed of two
CC       TGFBR1 and TGFBR2 heterodimers to form a ligand-receptor
CC       heterohexamer. The respective affinity of TGFRB1 and TGFRB2 for
CC       the ligands may modulate the kinetics of assembly of the receptor
CC       and may explain the different biological activities of TGFB1,
CC       TGFB2 and TGFB3. Interacts with DAXX. Interacts with TCTEX1D4.
CC       Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-
CC       beta receptor. Interacts with and is activated by SCUBE3; this
CC       interaction does not affect TGFB1-binding to TGFBR2. Interacts
CC       with VPS39; this interaction is independent of the receptor kinase
CC       activity and of the presence of TGF-beta.
CC       {ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11850637,
CC       ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:16982625,
CC       ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738,
CC       ECO:0000269|PubMed:21441952, ECO:0000269|PubMed:9865696}.
CC   -!- INTERACTION:
CC       Q9UER7:DAXX; NbExp=2; IntAct=EBI-296151, EBI-77321;
CC       Q93074:MED12; NbExp=3; IntAct=EBI-296151, EBI-394357;
CC       A2AGH6:Med12 (xeno); NbExp=3; IntAct=EBI-296151, EBI-5744969;
CC       Q8IX30:SCUBE3; NbExp=6; IntAct=EBI-296151, EBI-4479975;
CC       P01137:TGFB1; NbExp=6; IntAct=EBI-296151, EBI-779636;
CC       P07200:TGFB1 (xeno); NbExp=2; IntAct=EBI-296151, EBI-907660;
CC       P10600:TGFB3; NbExp=8; IntAct=EBI-296151, EBI-1033020;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1310899,
CC       ECO:0000269|PubMed:25893292}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:1310899}. Membrane raft
CC       {ECO:0000269|PubMed:25893292}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P37173-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P37173-2; Sequence=VSP_012157;
CC   -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic
CC       domain.
CC   -!- DISEASE: Hereditary non-polyposis colorectal cancer 6 (HNPCC6)
CC       [MIM:614331]: An autosomal dominant disease associated with marked
CC       increase in cancer susceptibility. It is characterized by a
CC       familial predisposition to early-onset colorectal carcinoma (CRC)
CC       and extra-colonic tumors of the gastrointestinal, urological and
CC       female reproductive tracts. HNPCC is reported to be the most
CC       common form of inherited colorectal cancer in the Western world.
CC       Clinically, HNPCC is often divided into two subgroups. Type I is
CC       characterized by hereditary predisposition to colorectal cancer, a
CC       young age of onset, and carcinoma observed in the proximal colon.
CC       Type II is characterized by increased risk for cancers in certain
CC       tissues such as the uterus, ovary, breast, stomach, small
CC       intestine, skin, and larynx in addition to the colon. Diagnosis of
CC       classical HNPCC is based on the Amsterdam criteria: 3 or more
CC       relatives affected by colorectal cancer, one a first degree
CC       relative of the other two; 2 or more generation affected; 1 or
CC       more colorectal cancers presenting before 50 years of age;
CC       exclusion of hereditary polyposis syndromes. The term 'suspected
CC       HNPCC' or 'incomplete HNPCC' can be used to describe families who
CC       do not or only partially fulfill the Amsterdam criteria, but in
CC       whom a genetic basis for colon cancer is strongly suspected.
CC       {ECO:0000269|PubMed:9590282}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of
CC       the esophagus. The most common types are esophageal squamous cell
CC       carcinoma and adenocarcinoma. Cancer of the esophagus remains a
CC       devastating disease because it is usually not detected until it
CC       has progressed to an advanced incurable stage.
CC       {ECO:0000269|PubMed:10789724}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Loeys-Dietz syndrome 2 (LDS2) [MIM:610168]: An aortic
CC       aneurysm syndrome with widespread systemic involvement,
CC       characterized by arterial tortuosity and aneurysms, hypertelorism,
CC       and bifid uvula or cleft palate. Physical findings include
CC       prominent joint laxity, easy bruising, wide and atrophic scars,
CC       velvety and translucent skin with easily visible veins,
CC       spontaneous rupture of the spleen or bowel, and catastrophic
CC       complications of pregnancy, including rupture of the gravid uterus
CC       and the arteries, either during pregnancy or in the immediate
CC       postpartum period. Some patients have craniosynostosis, exotropy,
CC       micrognathia and retrognathia, structural brain abnormalities, and
CC       intellectual deficit. {ECO:0000269|PubMed:15235604,
CC       ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16027248,
CC       ECO:0000269|PubMed:16251899, ECO:0000269|PubMed:19533785,
CC       ECO:0000269|PubMed:19883511, ECO:0000269|PubMed:20101701,
CC       ECO:0000269|PubMed:20358619, ECO:0000269|PubMed:21949523,
CC       ECO:0000269|PubMed:22113417}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. TGFBR2
CC       mutations Cys-460 and His-460 have been reported to be associated
CC       with thoracic aortic aneurysms and dissection (TAAD). This
CC       phenotype, also known as thoracic aortic aneurysms type 3 (AAT3),
CC       is distinguised from LDS2 by having aneurysms restricted to
CC       thoracic aorta. As individuals carrying these mutations also
CC       exhibit descending aortic disease and aneurysms of other arteries
CC       (PubMed:16027248), they have been considered as LDS2 by the OMIM
CC       resource. {ECO:0000269|PubMed:16027248}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfbr2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M85079; AAA61164.1; -; mRNA.
DR   EMBL; D28131; BAA05673.1; -; mRNA.
DR   EMBL; U52246; AAB17553.1; -; Genomic_DNA.
DR   EMBL; U52240; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52241; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52242; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52244; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52245; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U69152; AAB40916.1; -; Genomic_DNA.
DR   EMBL; U69146; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69147; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69148; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69149; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69150; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69151; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; D50683; BAA09332.1; -; mRNA.
DR   EMBL; AY675319; AAT70724.1; -; Genomic_DNA.
DR   EMBL; AK300383; BAG62117.1; -; mRNA.
DR   EMBL; CH471055; EAW64412.1; -; Genomic_DNA.
DR   CCDS; CCDS2648.1; -. [P37173-1]
DR   CCDS; CCDS33727.1; -. [P37173-2]
DR   PIR; A42100; A42100.
DR   RefSeq; NP_001020018.1; NM_001024847.2. [P37173-2]
DR   RefSeq; NP_003233.4; NM_003242.5. [P37173-1]
DR   UniGene; Hs.604277; -.
DR   UniGene; Hs.82028; -.
DR   PDB; 1KTZ; X-ray; 2.15 A; B=38-159.
DR   PDB; 1M9Z; X-ray; 1.05 A; A=49-159.
DR   PDB; 1PLO; NMR; -; A=38-159.
DR   PDB; 2PJY; X-ray; 3.00 A; B=42-149.
DR   PDB; 3KFD; X-ray; 3.00 A; E/F/G/H=38-153.
DR   PDB; 4P7U; X-ray; 1.50 A; A=49-159.
DR   PDB; 4XJJ; X-ray; 1.40 A; A=50-159.
DR   PDB; 5E8V; X-ray; 1.69 A; A=237-549.
DR   PDB; 5E8Y; X-ray; 2.05 A; A=237-549.
DR   PDB; 5E91; X-ray; 2.42 A; A=237-549.
DR   PDB; 5E92; X-ray; 2.08 A; A=237-549.
DR   PDB; 5TX4; X-ray; 1.88 A; A=38-153.
DR   PDBsum; 1KTZ; -.
DR   PDBsum; 1M9Z; -.
DR   PDBsum; 1PLO; -.
DR   PDBsum; 2PJY; -.
DR   PDBsum; 3KFD; -.
DR   PDBsum; 4P7U; -.
DR   PDBsum; 4XJJ; -.
DR   PDBsum; 5E8V; -.
DR   PDBsum; 5E8Y; -.
DR   PDBsum; 5E91; -.
DR   PDBsum; 5E92; -.
DR   PDBsum; 5TX4; -.
DR   ProteinModelPortal; P37173; -.
DR   SMR; P37173; -.
DR   BioGrid; 112906; 86.
DR   DIP; DIP-5939N; -.
DR   IntAct; P37173; 26.
DR   MINT; MINT-206666; -.
DR   STRING; 9606.ENSP00000351905; -.
DR   BindingDB; P37173; -.
DR   ChEMBL; CHEMBL4267; -.
DR   DrugBank; DB04077; Glycerol.
DR   GuidetoPHARMACOLOGY; 1795; -.
DR   iPTMnet; P37173; -.
DR   PhosphoSitePlus; P37173; -.
DR   BioMuta; TGFBR2; -.
DR   DMDM; 116242818; -.
DR   MaxQB; P37173; -.
DR   PaxDb; P37173; -.
DR   PeptideAtlas; P37173; -.
DR   PRIDE; P37173; -.
DR   DNASU; 7048; -.
DR   Ensembl; ENST00000295754; ENSP00000295754; ENSG00000163513. [P37173-1]
DR   Ensembl; ENST00000359013; ENSP00000351905; ENSG00000163513. [P37173-2]
DR   GeneID; 7048; -.
DR   KEGG; hsa:7048; -.
DR   UCSC; uc003cen.4; human. [P37173-1]
DR   CTD; 7048; -.
DR   DisGeNET; 7048; -.
DR   GeneCards; TGFBR2; -.
DR   GeneReviews; TGFBR2; -.
DR   H-InvDB; HIX0024332; -.
DR   HGNC; HGNC:11773; TGFBR2.
DR   HPA; CAB073537; -.
DR   MalaCards; TGFBR2; -.
DR   MIM; 133239; phenotype.
DR   MIM; 190182; gene.
DR   MIM; 610168; phenotype.
DR   MIM; 614331; phenotype.
DR   neXtProt; NX_P37173; -.
DR   OpenTargets; ENSG00000163513; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 144; Hereditary nonpolyposis colon cancer.
DR   Orphanet; 60030; Loeys-Dietz syndrome.
DR   Orphanet; 284973; Marfan syndrome type 2.
DR   PharmGKB; PA36486; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   eggNOG; ENOG410XS2Z; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000231495; -.
DR   HOVERGEN; HBG104975; -.
DR   InParanoid; P37173; -.
DR   KO; K04388; -.
DR   OMA; TRHIISW; -.
DR   PhylomeDB; P37173; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer.
DR   Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer.
DR   Reactome; R-HSA-3642279; TGFBR2 MSI Frameshift Mutants in Cancer.
DR   Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer.
DR   Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer.
DR   Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer.
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   SignaLink; P37173; -.
DR   SIGNOR; P37173; -.
DR   ChiTaRS; TGFBR2; human.
DR   EvolutionaryTrace; P37173; -.
DR   GeneWiki; TGF_beta_receptor_2; -.
DR   GenomeRNAi; 7048; -.
DR   PRO; PR:P37173; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000163513; -.
DR   CleanEx; HS_TGFBR2; -.
DR   ExpressionAtlas; P37173; baseline and differential.
DR   Genevisible; P37173; HS.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0070022; C:transforming growth factor beta receptor complex; IC:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL.
DR   GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IEA:Ensembl.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001568; P:blood vessel development; TAS:BHF-UCL.
DR   GO; GO:0007420; P:brain development; ISS:BHF-UCL.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060434; P:bronchus morphogenesis; IEA:Ensembl.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:BHF-UCL.
DR   GO; GO:0003274; P:endocardial cushion fusion; ISS:BHF-UCL.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0003430; P:growth plate cartilage chondrocyte growth; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:1990086; P:lens fiber cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl.
DR   GO; GO:0060443; P:mammary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0003149; P:membranous septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; ISS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0002663; P:positive regulation of B cell tolerance induction; ISS:BHF-UCL.
DR   GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0051138; P:positive regulation of NK T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0043415; P:positive regulation of skeletal muscle tissue regeneration; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0002666; P:positive regulation of T cell tolerance induction; ISS:BHF-UCL.
DR   GO; GO:0002651; P:positive regulation of tolerance induction to self antigen; ISS:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IDA:BHF-UCL.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001570; P:vasculogenesis; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   InterPro; IPR017194; Transform_growth_fac-b_typ-2.
DR   InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF08917; ecTbetaR2; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF037393; TGFRII; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis;
KW   ATP-binding; Cell membrane; Complete proteome; Differentiation;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Growth regulation;
KW   Hereditary nonpolyposis colorectal cancer; Kinase; Magnesium;
KW   Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        23    567       TGF-beta receptor type-2.
FT                                /FTId=PRO_0000024426.
FT   TOPO_DOM     23    166       Extracellular. {ECO:0000255}.
FT   TRANSMEM    167    187       Helical. {ECO:0000255}.
FT   TOPO_DOM    188    567       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      244    544       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     250    258       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    379    379       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     277    277       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     409    409       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62312}.
FT   MOD_RES     548    548       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     553    553       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62312}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     94     94       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    154    154       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     51     84       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     54     71       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     61     67       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     77    101       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID    121    136       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID    138    143       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   VAR_SEQ      31     32       SV -> SDVEMEAQKDEIICPSCNRTAHPLRHI (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:7959019}.
FT                                /FTId=VSP_012157.
FT   VARIANT      36     36       M -> V (in dbSNP:rs17025864).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_020510.
FT   VARIANT      61     61       C -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041414.
FT   VARIANT      73     73       I -> V (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036070.
FT   VARIANT     190    190       R -> H (in LDS2; dbSNP:rs780542125).
FT                                {ECO:0000269|PubMed:19533785}.
FT                                /FTId=VAR_076167.
FT   VARIANT     191    191       V -> I (in dbSNP:rs56105708).
FT                                {ECO:0000269|PubMed:12202987,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_017606.
FT   VARIANT     247    247       D -> V (in LDS2; dbSNP:rs761231369).
FT                                {ECO:0000269|PubMed:19533785}.
FT                                /FTId=VAR_076168.
FT   VARIANT     306    306       Q -> HE (in LDS2).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066723.
FT   VARIANT     308    308       L -> P (in LDS2; has a negative effect on
FT                                TGF-beta signaling; dbSNP:rs28934568).
FT                                {ECO:0000269|PubMed:15235604,
FT                                ECO:0000269|PubMed:20358619}.
FT                                /FTId=VAR_022351.
FT   VARIANT     315    315       T -> M (in HNPCC6; dbSNP:rs34833812).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9590282}.
FT                                /FTId=VAR_008156.
FT   VARIANT     325    325       T -> P (in LDS2).
FT                                {ECO:0000269|PubMed:19533785}.
FT                                /FTId=VAR_076169.
FT   VARIANT     328    328       H -> Y (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041415.
FT   VARIANT     336    336       Y -> N (in LDS2; dbSNP:rs104893812).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022352.
FT   VARIANT     355    355       A -> P (in LDS2; dbSNP:rs104893813).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022353.
FT   VARIANT     357    357       G -> R (in LDS2).
FT                                {ECO:0000269|PubMed:19533785}.
FT                                /FTId=VAR_076170.
FT   VARIANT     357    357       G -> W (in LDS2; dbSNP:rs104893814).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022354.
FT   VARIANT     373    373       M -> I (in dbSNP:rs35719192).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041416.
FT   VARIANT     377    377       H -> R (in LDS2).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066724.
FT   VARIANT     387    387       V -> M (in a breast tumor;
FT                                dbSNP:rs35766612).
FT                                {ECO:0000269|PubMed:11212236,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_022355.
FT   VARIANT     435    435       N -> S (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                {ECO:0000269|PubMed:11212236}.
FT                                /FTId=VAR_022356.
FT   VARIANT     439    439       V -> A (in dbSNP:rs1050833).
FT                                {ECO:0000269|PubMed:1310899,
FT                                ECO:0000269|PubMed:8812462,
FT                                ECO:0000269|PubMed:8840968,
FT                                ECO:0000269|PubMed:8973329}.
FT                                /FTId=VAR_028063.
FT   VARIANT     446    446       D -> N (in LDS2).
FT                                {ECO:0000269|PubMed:16251899}.
FT                                /FTId=VAR_066725.
FT   VARIANT     447    447       V -> A (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                {ECO:0000269|PubMed:11212236}.
FT                                /FTId=VAR_022357.
FT   VARIANT     449    449       S -> F (in LDS2; has a negative effect on
FT                                TGF-beta signaling; dbSNP:rs104893807).
FT                                {ECO:0000269|PubMed:15235604,
FT                                ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_022358.
FT   VARIANT     452    452       L -> M (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                {ECO:0000269|PubMed:11212236}.
FT                                /FTId=VAR_022359.
FT   VARIANT     457    457       M -> K (in LDS2).
FT                                {ECO:0000269|PubMed:20101701}.
FT                                /FTId=VAR_066726.
FT   VARIANT     460    460       R -> C (in LDS2; dbSNP:rs104893811).
FT                                {ECO:0000269|PubMed:16027248}.
FT                                /FTId=VAR_029760.
FT   VARIANT     460    460       R -> H (in LDS2; dbSNP:rs104893816).
FT                                {ECO:0000269|PubMed:16027248}.
FT                                /FTId=VAR_029761.
FT   VARIANT     490    490       N -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041417.
FT   VARIANT     509    509       G -> V (in LDS2; dbSNP:rs863223853).
FT                                {ECO:0000269|PubMed:21949523}.
FT                                /FTId=VAR_066727.
FT   VARIANT     510    510       I -> F (in LDS2).
FT                                {ECO:0000269|PubMed:21949523}.
FT                                /FTId=VAR_066728.
FT   VARIANT     510    510       I -> S (in LDS2).
FT                                {ECO:0000269|PubMed:19883511}.
FT                                /FTId=VAR_066729.
FT   VARIANT     514    514       C -> R (in LDS2; dbSNP:rs193922664).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066730.
FT   VARIANT     521    521       W -> R (in LDS2).
FT                                {ECO:0000269|PubMed:20358619}.
FT                                /FTId=VAR_066731.
FT   VARIANT     526    526       E -> Q (in esophageal cancer;
FT                                dbSNP:rs121918714).
FT                                {ECO:0000269|PubMed:10789724}.
FT                                /FTId=VAR_015816.
FT   VARIANT     528    528       R -> C (in LDS2; dbSNP:rs104893810).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022360.
FT   VARIANT     528    528       R -> H (in LDS2; dbSNP:rs104893815).
FT                                {ECO:0000269|PubMed:15731757,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_022361.
FT   VARIANT     530    530       T -> I (in LDS2).
FT                                {ECO:0000269|PubMed:19533785}.
FT                                /FTId=VAR_076171.
FT   VARIANT     537    537       R -> C (in LDS2; has a negative effect on
FT                                TGF-beta signaling; dbSNP:rs28934869).
FT                                {ECO:0000269|PubMed:15235604}.
FT                                /FTId=VAR_022362.
FT   MUTAGEN     277    277       K->R: Abolishes kinase activity, TGF-beta
FT                                signaling and interaction with DAXX.
FT                                {ECO:0000269|PubMed:11483955}.
FT   CONFLICT    381    381       K -> N (in Ref. 6; BAA09332).
FT                                {ECO:0000305}.
FT   STRAND       40     45       {ECO:0000244|PDB:1PLO}.
FT   STRAND       50     52       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       55     58       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       65     68       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       74     76       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       78     81       {ECO:0000244|PDB:1PLO}.
FT   STRAND       83     90       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       95    102       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      106    110       {ECO:0000244|PDB:3KFD}.
FT   TURN        114    117       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      119    122       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      124    126       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      131    138       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      140    142       {ECO:0000244|PDB:1PLO}.
FT   HELIX       143    145       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      146    148       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      149    154       {ECO:0000244|PDB:1PLO}.
FT   STRAND      244    252       {ECO:0000244|PDB:5E8V}.
FT   STRAND      257    263       {ECO:0000244|PDB:5E8V}.
FT   STRAND      273    280       {ECO:0000244|PDB:5E8V}.
FT   HELIX       281    283       {ECO:0000244|PDB:5E8V}.
FT   HELIX       284    294       {ECO:0000244|PDB:5E8V}.
FT   HELIX       297    299       {ECO:0000244|PDB:5E8V}.
FT   STRAND      307    314       {ECO:0000244|PDB:5E8V}.
FT   STRAND      316    326       {ECO:0000244|PDB:5E8V}.
FT   HELIX       333    339       {ECO:0000244|PDB:5E8V}.
FT   HELIX       344    362       {ECO:0000244|PDB:5E8V}.
FT   HELIX       382    384       {ECO:0000244|PDB:5E8V}.
FT   STRAND      385    387       {ECO:0000244|PDB:5E8V}.
FT   STRAND      393    395       {ECO:0000244|PDB:5E8V}.
FT   TURN        410    414       {ECO:0000244|PDB:5E8V}.
FT   HELIX       422    424       {ECO:0000244|PDB:5E8V}.
FT   HELIX       427    430       {ECO:0000244|PDB:5E8V}.
FT   HELIX       439    459       {ECO:0000244|PDB:5E8V}.
FT   HELIX       462    464       {ECO:0000244|PDB:5E8V}.
FT   TURN        473    477       {ECO:0000244|PDB:5E8V}.
FT   HELIX       484    491       {ECO:0000244|PDB:5E8V}.
FT   TURN        492    494       {ECO:0000244|PDB:5E8V}.
FT   HELIX       502    506       {ECO:0000244|PDB:5E8V}.
FT   HELIX       508    520       {ECO:0000244|PDB:5E8V}.
FT   HELIX       525    527       {ECO:0000244|PDB:5E8V}.
FT   HELIX       531    540       {ECO:0000244|PDB:5E8V}.
SQ   SEQUENCE   567 AA;  64568 MW;  C541DA751FFBDBEB CRC64;
     MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST
     CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK
     CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI
     SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE
     LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK
     HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH
     LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG
     TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE
     HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE
     LEHLDRLSGR SCSEEKIPED GSLNTTK
//
